Lixte Biotechnology Holdings Inc. (LIXT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lixte Biotechnology Holdings Inc. (LIXT:NASDAQ), powered by AI.

Current Price
$6.88
P/E Ratio
-5.5
Market Cap
33M
Sector
Healthcare
What is the Lixte Biotechnology Holdings Inc. stock price forecast?

Lixte Biotechnology Holdings Inc. is currently trading at $6.88. View real-time AI analysis on Alpha Lenz.

What is Lixte Biotechnology Holdings Inc. insider trading activity?

View the latest insider trading data for Lixte Biotechnology Holdings Inc. on Alpha Lenz.

What is Lixte Biotechnology Holdings Inc.'s P/E ratio?

Lixte Biotechnology Holdings Inc.'s P/E ratio is -5.5.

Lixte Biotechnology Holdings Inc.

NASDAQ · LIXT
$6.88+0.16(+2.38%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Lixte Biotechnology Holdings Inc.'s future dividend policy...
Alpha Chat Insight

Lixte Biotechnology Holdings Inc. trades at a P/E of -5.5 (undervalued) with modest ROE of -114.6%.

Ask for details

Company Overview

Lixte Biotechnology Holdings Inc. is a biotechnology company specializing in the research and development of treatments aimed at addressing various forms of cancer and other serious diseases. The primary function of Lixte is to innovate in the field of drug development by focusing on novel compounds that can serve as potential therapeutics. Notably, the company concentrates on identifying and developing small molecule inhibitors that target specific pharmacological pathways involved in cancer progression and other diseases. Lixte operates primarily within the biotechnology and pharmaceutical sectors, holding significance for its contribution to potentially groundbreaking cancer therapies. By focusing on a niche market in oncology and the broader healthcare industry, Lixte Biotechnology Holdings Inc. plays a critical role in advancing scientific research and offering new hope in the fight against complex diseases. Its activities exemplify the intersection of cutting-edge science and the quest for effective clinical solutions in a highly dynamic and innovative sector.

CEOMr. Geordan G. Pursglove
SectorHealthcare
IndustryBiotechnology
Employees2

Company Statistics

FY 2025

Profile

$33.30MMarket Cap
$0.00Revenue
0.00Shares Out
2Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-5.54P/E
3.45P/B
N/AEV/Sales
-5.92EV/EBITDA
-10.85P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-86.60%ROA
-114.56%ROE
-86.47%ROIC

Financial Health

$5.11MCash & Cash Equivalents
$-3.33MNet Debt
16.17%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Lixte Biotechnology Holdings Inc. (ticker: LIXT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2 employees. Market cap is $33M.

The current price is $6.88 with a P/E ratio of -5.54x and P/B of 3.45x.

ROE is -114.56%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Lixte Biotechnology Holdings Inc. (LIXT) Stock Forecast 2026 $6.88 — Price, Financials & Analyst Targets | Alpha Lenz